AQUA BIO TECHNOLOGY ASA – PRIMARY INSIDER NOTIFICATIONS

13.12.2021 00:40:04 CET | Aqua Bio Technology ASA | Mandatory notification of trade primary insiders
Aqua Bio Technology ASA – Primary insider Notifications
Reference is made to the stock exchange notice from Aqua Bio Technology ASA (the “Company”) regarding the completion of a private placement to raise NOK 12.89 million.
In the private placement Håvard Lindstrøm, CEO and primary insider the Company, has been allocated 71 429 shares at a price of NOK 14 per share, through his wholly owned company Ice Capital AS. Following such allocation, Håvard Lindstrøm and related parties will, upon issuance of shares in the private placement, hold 416 348 shares in the Company, corresponding to an ownership stake of 2.0% of the total outstanding shares in the Company.
Roger Hofseth, board member and primary insider of ABT, has been allocated 178 571 shares today at a price of NOK 14 per share, through his wholly owned company RH Industri AS. Following such allocation, Roger Hofseth and related parties will, upon issuance of shares in the private placement, hold 4 693 475 shares in the Company, corresponding to an ownership stake of 22.76% of the total outstanding shares in the Company.
Jan Petterson, board member and primary insider of ABT, has been allocated 107 143 shares  today at a price of NOK 14 per share. Following such allocation, Jan Petterson and related parties will, upon issuance of shares in the private placement, hold 4 543 028 shares in the Company, corresponding to an ownership stake of 22.03% of the total outstanding shares in the Company.
Espen Halvard Dahl, a close associate of Board member Kristin Aase who is a primary insider in the Company, has been allocated 71 429 shares at a price of NOK 14. Following such allocation, Espen Halvard Dahl, Kjeveortoped Espen Dahl AS and close associates (including Board member Kristin Aase) will, upon issuance of shares in the private placement, hold 1 477 707 shares in the company, corresponding to an ownership stake of 7.17% of the total outstanding shares in the Company.
Further information is available in the attached forms.
****
For further information, please contact Håvard Lindstrøm, CEO, telephone +47 941 32 288.
This information is subject to the disclosure requirements in Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act § 5-12.
Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT’s cosmetics ingredients are effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. ABT’s focus on commercialization and development of natural ingredients and natural skin care products has been, and will continue to be, an important part of the company’s strategy going forward. Aqua Bio Technology is listed on Euronext Expand.
 
Disclosure regulation
This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.
Contacts

Håvard Lindstrøm, 004794132288, hl@aquabiotech.no

About Aqua Bio Technology ASA
Aqua Bio Technology (ABT) is developing and commercializing sustainablebiotechnology for use in skin care products. ABT’s cosmetics ingredients arehighly effective and they provide the cosmetics industry with naturalalternatives to traditional ingredients. ABT is also marketing and distributingnatural skin care products developed by partners towards consumers andprofessional users. Aqua Bio Technology is listed on Euronext Expand.
Attachments

Download announcement as PDF.pdf

Ice Capital AS.pdf

RH Industri AS.pdf

EH Dahl Jan Petterson.pdf

Leave a Reply